mb07133
Safety Issues
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Safety Issues cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Remifemin Zhejiang Cancer Hospital | Phase 2 | B |
Irinotecan Assiut University | Phase 2 | B |
(+)-VINCRISTINE Assiut University | Phase 2 | B |
Nivolumab Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | CCC |
Cyclophosphamide The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
View all 26 →
Same molecule, other indications
mb07133 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →